Diasorin S.p.A./  IT0003492391  /

DiaSorin S.p.A.is an international player in the market for in vitro diagnostics, a specific segment of immunodiagnostics that encompasses the categories of immunochemistry and infectious immunology. The expression “in vitro” designates the market for diagnostic products used to test samples taken from patients (blood, urine, etc.), as separate from in vivo, or injectable, products, which are administered to patients directly. The products developed and distributed by the DiaSorin Group are designed specifically for clinical diagnostics applications. They are used by diagnostic laboratories that are part of hospital facilities or operate independently (private diagnostic services laboratories). For the most part, they help physicians in diagnosing different diseases (diagnostic benefit), determining the progress of a disease (prognostic benefit) and assessing the effectiveness of a drug treatment (monitoring benefit). The Group is comprised of six industrial sites and five research facilities and 27 companies and its direct sales network, supported by an international network of almost 100 independent distributors. DiaSorin S.p.A. is headquartered in Saluggia (Vercelli), Italy.